Upcoming Chamber Events

Cambridge Chamber to Host Stakeholder Briefing on FDA's PDUFA Reauthorization 

Why PDUFA Matters 

Every five years, Congress and the FDA work together to reauthorize the Prescription Drug User Fee Act (PDUFA), the law that determines how the agency funds and conducts its review of new drug applications. On paper, it's a technical, procedural process. In practice, the stakes are high. PDUFA shapes how quickly and predictably new treatments move through the FDA pipeline, and for a region built on life sciences innovation, that timeline matters to Bay Staters, from the companies developing new therapies to the patients waiting on them. 

Bringing the Conversation Home 

With the next reauthorization cycle approaching, the Cambridge Chamber of Commerce is bringing that conversation home. On Tuesday, October 20, the Chamber will host a PDUFA Stakeholder Briefing in Cambridge, MA, giving the local biotech and pharmaceutical community a direct line to the stakeholders shaping this round of negotiations. 

Cambridge is one of the most concentrated life sciences hubs in the country. The outcome of PDUFA reauthorization touches nearly every company here, from early-stage biotechs waiting on their first approval to established pharmaceutical players managing a full portfolio of applications. This briefing is a chance to see what's in the pipeline and to make sure the priorities of Cambridge-based companies are aligned before terms are finalized. 

Part of a National Conversation 

This is not the only PDUFA event this year. It's one stop in a broader series of stakeholder briefings taking place across the country this fall, part of a national effort to gather input from industry ahead of reauthorization. That national scope is worth noting: decisions made in this cycle will affect drug review timelines and FDA resources nationwide, and regional voices, including Cambridge's, have a real opportunity to shape the outcome.